George A. Eldridge, SEE REMARKS at Aerovate Therapeutics, Inc. (AVTE), sold 8,134 shares at $25.02 ($204K) on 2024-03-13, disclosed to the SEC on 2024-03-14.
Scheduled sale ($204k) by SEE REMARKS under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $25.05 | 2,051 | $51K | 25.2% |
| 2 | $25.05 | 2,051 | $51K | 25.2% |
| 3 | $25.02 | 2,016 | $50K | 24.8% |
| 4 | $25.02 | 2,016 | $50K | 24.8% |
| Total | $25.04 avg | 8,134 | $204K | 100% |
| Filing → |
| AVTE | SELL | 2024-04-03 | $780K | — | Filing → |
| AVTE | SELL | 2024-03-11 | $736K | — | Filing → |
| AVTE | SELL | 2022-12-13 | $479K | — | Filing → |